Salvage therapy for hepatocellular carcinoma with thalidomide

World Journal of Gastroenterology

Volumn 10, Issue 5, 2004, Pages 649-653

  Wang, Tsang En ^a   Kao, Chin Roa ^a   Lin, Shee Chan ^a   Chang, Wen Hsiung ^a   Chu, Cheng Hsin ^a   Lin, Johson ^a   Hsieh, Ruey Kuen ^a  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ANTIHISTAMINIC AGENT; LAXATIVE; THALIDOMIDE;

ADULT; ADVANCED CANCER; AGED; ALCOHOL LIVER CIRRHOSIS; ARTICLE; CANCER STAGING; CONSTIPATION; CONTROLLED STUDY; DATA ANALYSIS; DERMATITIS; DIAGNOSTIC IMAGING; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEUROPATHY; PREDICTION; PROGNOSIS; PRURITUS; SALVAGE THERAPY; SKIN TOXICITY; SOMNOLENCE; SURVIVAL TIME; TREATMENT FAILURE; TUMOR CLASSIFICATION; URTICARIA; VIRUS HEPATITIS;

EID: 1542790477     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v10.i5.649     Document Type: Article

References (30)

1. Lin SC, Shih SC, Kao CR, Chou SY. Transcatheter arterial embolization treatment in patients with hepatocellular carcinoma and risk of pulmonary metastasis. World J Gastroenterol 2003; 9: 1208-1211
2. Folkman J, Watson K, higber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339: 58-61
3. Patt YZ, Hassan MM, Lozano RD, Ellis LM, Peterson JA, Waugh KA. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am J Clin Oncol 2000; 23: 319-321
4. Lin AY, Brophy N, Fisher GA, So S, Biggs C, Yock T, Levitt L. Phase II study of thalidomide in patients (pts) with unresectable hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 2002; 21: P97b abstr:2202
5. Kong HL, Boyer MJ, Lim R, Clarke S, Milward JM, Wong E. Phase II trial of thalidomide in unresectable hepatocellular carcinoma (HCC)-a cancer therapeutics group (CTRG) study. Proc Am Soc Clin Oncol 2001; 20: p133b, abstr: 2282
6. Patt YZ, Hassan MM, Lozano RD, Zeldis JB, Schnirer I, Frome A, Abbruzzese J, Wolff R, Brwom T, Lee E, Charnsangavej C. Phase II trial of thalidomide for treatment of nonresectable hepatocellular carcinoma. Proc Am Soc Clin Oncol 2000; 14(Suppl 12, abstr): 1035
7. Schwartz JD, Sung Max W, Lehrer D, Goldenberg A, Muggia F, Volm M. Thalidomide for unresectable hepatocellular cancer (HCC) with optional interferon-\upon disease progression. Proc Am Soc Clin Oncol 2002 abstr: 1847
8. Jacqueline WP, Chen LT. Thalidomide and hepatoma. NHRI-AACR Joint Conference 2001 abstr: 653. (The Fifth Taiwan Cancer Clinical Research Organization Cooperative Annual Conference and Cross-Strait Anti-Cancer Pharmaceuticals Research and Development Conference.) http://tpmd.nhri.org.tw/~scba/php-bin/scba2001/abstract/abs653.htm
9. The Cancer of the Liver Italian Program (CLIP) Investigators. Prospective validation of the CLIP Score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000; 31: 840-845
10. Cori V. Preparing for thalidomide's comeback. Ann Internl Med 1997; 127: 951-952
11. Calabrese L, Fleischer AB. Thalidomide current and potential clinical applications. Am J Med 2000; 108: 487-495
12. Moriera AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor [alpha] by enhancing mRNA degradation. J Exp Med 1993; 177: 1675-1680
13. Gad SM, Shannon EJ, Krotoski WA, Hastings RC. Thalidomide induces imbalances in T-lymphocyte subpopulations in the circulating blood of healthy males. Lepr Rev 1985; 56: 35-39
14. Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+subset. J Exp Med 1998; 187: 1885-1892
15. Verbon A, Juffermans NP, Speelman P, van Deventer SJ, ten Berge IJ, Guchelaar HJ, van der Poll T. A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans. Antimicrobl Agents Chemotherr 2000; 44: 2286-2290
16. Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 1998; 55: 1827-1834
17. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994; 91: 4082-4085
18. Konno H. Antitumor effect of angiogenesis inhibitor TNP-470 on human digestive organ malignancy. Cancer Chemother Pharmacol 1999; 43(Suppl): S85-89
19. Wordemann M, Fandrey J, Jelkmann W. Tumor necrosis factor-alpha production by human hepatoma cell lines is resistant to drugs that are inhibitory to macrophages. J Interferon Cytokine Res 1998; 18: 1069-1075
20. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, Treon SP, Richardson PG, Schlossman RL, Morgan GJ, Muller GW, Stirling DI, Anderson KC. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210-216
21. Hui AM, Kawasaki S, Imamura H, Miyagawa S, Ishii K, Ratsuyama T, Makuuchi M. Heterogeneity of DNA content in multiple synchronous hepatocellular carcinomas. Br J Cancer 1997; 76: 335-339
22. Maksan SM, Paulo H, Ryschich E, Kuntz C, Gebhard MM, Klar E, Schmidt J. In vivo assessment of angioarchitecture and microcirculation in experimental liver cancer: A new model in rats. Dig Dis Sci 2003; 48: 279-290
23. Wei Y, Van Nhieu JT, Prigent S, Srivatanakul P, Tiollais P, Buendia MA. Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features. Hepatology 2002; 36: 692-701
24. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K. Nature history of hepatocellular carcinoma and prognosis in relation to treatment-study of 850 patients. Cancer 1985; 56: 918-928
25. Neben K, Moehler T, Benner A, Kraemer A, Egerer G, Ho AD, Goldschmidt H. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 2002; 8: 3377-3382
26. Feun LG, Marini A, Molina E, O'Brien C, Schiff E, Jeffers L, Savaraj N. Thalidomide as palliative care for patients with unresectable hepatocellular carcinoma. Proc Am Soc Clin Oncol 2003; abstr: 865
27. von Moos R, Stolz R, Cerny T, Gillessen S. Thalidomide; from tragedy to promise. Swiss Med WKLY 2003; 133: 77-87
28. Schwartz JD, Lehrer D, Mandeli J, Goldenberg A, Sung M, Volm M. Thalidomide in hepatocellular cancer (HCC) with optional interferon-\upon progression. Proc Am Soc Clin Oncol 2003; abstr: 1210
29. Chun HG, Waheed F, Iqbal A, Wolf DC, Li Z, Kempin SJ. A combination of capecitabine and thalidomide in patients with unresectable, recurrent or metastatic hepatocellular carcinoma. Proc Am Soc Clin Oncol 2003; Abstr: 1407
30. Chen CS, Hillebrand D, Hill K, Lilly M. A pilot study of celecoxib combined with escalating doses of thalidomide for treatment of unresectable hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 2002; abstr: 2350